Welcome to our dedicated page for Nrx Pharmaceuticals news (Ticker: NRXP), a resource for investors and traders seeking the latest updates and insights on Nrx Pharmaceuticals stock.
NRx Pharmaceuticals, Inc. reports clinical, regulatory, manufacturing, and subsidiary developments for a biopharmaceutical business focused on neuroplastic therapies for depression, PTSD, suicidality, and related conditions. Company updates center on NRX-100 preservative-free ketamine, NRX-101 as a D-cycloserine/lurasidone fixed-dose combination, FDA communications, generic-drug and new-drug application pathways, and clinical work involving treatment-resistant depression and suicidality.
Recurring news also covers commercial manufacturing preparations, drug-shortage context for ketamine injection, robotic-enabled transcranial magnetic stimulation initiatives through NRx Defense Systems, and interventional psychiatry activity through HOPE Therapeutics. Additional company developments include partnerships involving digital monitoring tools, leadership appointments, and research programs serving military, first-responder, and broader behavioral-health settings.
HOPE Therapeutics (Nasdaq: NRXP) opened a Palm Beach, FL clinic on March 9, 2026, offering one‑day interventional psychiatry treatments for depression and PTSD that combine ketamine and other neuroplastic drugs, transcranial magnetic stimulation (TMS), hyperbaric oxygen, and physician‑led psychotherapy.
Peer‑reviewed publications cited an 87% clinical response rate for a short‑term TMS plus neuroplastic medication protocol; pilot programs with added hyperbaric oxygen reported a 90% return to full function rate. HOPE cites a nationwide partnership with neurocare AG and is now accepting patients by phone.
NRx Pharmaceuticals (Nasdaq: NRXP) appointed Prof. Joshua C. Brown, MD, PhD, as Chief Medical Innovation Officer effective March 2, 2026. Prof. Brown is a TMS pioneer, Harvard-affiliated clinician-scientist with >$20M in federal funding, and will guide NRx's work combining TMS with neuroplastic medications including NRX-101.
He will collaborate with NRx leadership on development programs and an FDA Investigational New Drug application to test a combined therapy for PTSD and depression in first responders and military personnel.
NRx Pharmaceuticals (Nasdaq: NRXP) completed a Type C meeting with FDA leadership on Feb 17, 2026 and received oral guidance that supports a path to a New Drug Application for NRX-100 (preservative-free ketamine).
The company plans to combine existing adequate, well-controlled trial data with Real World Evidence from >65,000 patients and will seek a broader indication for treatment-resistant depression with suicidality. FDA preliminarily advised no additional nonclinical data or bridging studies would be required. Final meeting minutes and a finalized statistical analysis protocol for the RWE dataset are pending.
NRx Pharmaceuticals (Nasdaq: NRXP) will hold its 2025 annual meeting of stockholders on March 23, 2026 at 10:00 a.m. ET in a virtual-only format at https://www.cstproxy.com/nrxpharma/2026. The Board set a record date of February 12, 2026 for stockholders entitled to notice and to vote. The company said its proxy statement, to be filed with the SEC prior to the meeting, will describe meeting matters and voting procedures.
Because the meeting date is more than 60 days after the prior meeting anniversary, the advance-notice deadline under the bylaws for stockholder proposals and director nominations (other than Rule 14a-8 submissions) is the close of business on January 26, 2026. Submissions must follow the bylaws and be delivered by hand, overnight courier, or certified/registered mail to the company’s principal executive offices.
Bright Mountain Media (OTCQB: BMTM) released an on-demand webinar, “How Connected Research Helped Aruba Reimagine Tourism Marketing,” detailing a sub-30-minute case study of Aruba Tourism Authority, Big Village, and Deep Focus. The campaign shifted messaging to attitudinal segments, linked media activations to CRM, and reportedly delivered record visitation and improved marketing ROI. The campaign won a Gold Magellan Award and Shorty Impact recognition. The company also disclosed CEO Matt Drinkwater purchased 299,500 shares on December 10, 2025 (Form 5 filed).
NRx Pharmaceuticals (Nasdaq: NRXP) will submit real-world evidence from over 70,000 patients treated with intravenous ketamine or nasal S-ketamine to the FDA to support an Accelerated Approval application for NRX-100 (preservative-free ketamine) under Fast Track designation for treatment of suicidal ideation in depression, including bipolar depression.
The RWE, supplied by Osmind, includes nearly 1 million treatment sessions, continuous vitals, safety elements, and a prior 20,000-patient analysis showing rapid resolution of depression and suicidality.
NRx Pharmaceuticals (Nasdaq: NRXP) and neurocare Group AG announced a partnership to create a nationwide network of clinics delivering integrated neuroplastic therapy for Depression, PTSD, and other CNS disorders.
The program will combine TMS, ketamine and other neuroplastic drugs, hyperbaric oxygen, psychotherapy, telepsychiatry, and shared training; partners cite published results showing 87% response and 72% remission in treatment‑resistant depression and a pilot showing high remission rates in first responders. The partners plan to leverage > 400 Apollo® TMS devices, ~20 US clinics, and aim for driving‑distance access across the US by year‑end 2026, while exploring clinical trials for additional indications.
NRx Pharmaceuticals (Nasdaq: NRXP) said it eliminated its remaining balance sheet debt after converting the final $5.4 million owed to Anson Funds into common stock with no warrants or repricing provisions.
The company noted Anson originally lent $16.2 million to fund prior loans and operating expenses and that it expects to end Dec 31, 2025 with a debt-free balance sheet. Management said the debt-free capital structure positions the company for potential drug approvals and clinic expansions in 2026.
NRx Pharmaceuticals (Nasdaq: NRXP) amended its Investigational New Drug filing for NRX-101 (D-cycloserine/lurasidone) to add use in combination with Transcranial Magnetic Stimulation (TMS) for treatment of depression, including suicidal depression, and will offer the protocol via clinical trial and Expanded Access.
Company holds >25,000 investigational doses, cites prior studies reporting 75% response/40% remission (Cole et al.) and real-world data with 87% response/72% remission at 6 weeks after a single-day TMS+DCS regimen, and says NRX-101 has composition-of-matter patents and Breakthrough Therapy designation.
NRx Pharmaceuticals (NASDAQ: NRXP) announced the FDA has received and deemed substantially complete its Abbreviated New Drug Application (ANDA) for KETAFREE™, a preservative-free IV ketamine. The FDA assigned a GDUFA goal date of July 29, 2026 for final review. NRx manufactured initial registration lots, can scale to 1 million vials per month, and seeks KETAFREE™ as a proprietary name. The company estimates the current worldwide generic ketamine market at $750 million per year and is awaiting an FDA response to an August citizen petition about Benzethonium Chloride removal. KETAFREE™ is separate from NRx’s NRX-100 program.